ArticleChemistry & biodiversity2026
Dahuang Huanglian Xiexin Decoction Ameliorates Obesity by Targeting the PPARγ/STAT3/PTGS2 Axis: Integrative Network Pharmacology and Experimental Validation.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Childhood obesity is a major preventable health issue. This study evaluated the anti-obesity effects of Dahuang Huanglian Xiexin Decoction (DHXD) and explored its potential mechanisms using network pharmacology and molecular docking. Active compounds and targets of DHXD were identified from TCMSP and HERB databases, while obesity-related targets were obtained from GeneCards, TTD, and DisGeNET. A protein-protein interaction network helped identify 45 shared targets and 10 hub genes. Molecular docking confirmed strong binding between DHXD components and key targets. An obesity rat model was established using a high-fat diet, followed by DHXD treatment. Parameters such as body weight, fat mass, and rectal temperature were monitored. Biochemical assays and histological staining assessed metabolic and tissue changes. Western blotting evaluated the expression of obesity-related proteins. Results showed DHXD significantly reduced body weight and fat accumulation, improved blood glucose and lipid profiles, and promoted lipolysis and browning of white adipose tissue. Molecular analysis highlighted PPARγ, PTGS2, and STAT3 as central targets mediating DHXD's anti-obesity effects. These findings support the potential of DHXD as an effective therapeutic agent against obesity and provide insights into its molecular mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.